ホーム › 急性骨髄性白血病 › アイオワ州 › Cedar Rapids
Cedar Rapids、IAにおける急性骨髄性白血病の臨床試験
Cedar Rapidsとその周辺地域（約30マイル以内）の拠点で、急性骨髄性白血病に関する16件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
被験者募集中観察研究健康なボランティア歓迎
- Mercy Hospital, Cedar Rapids
- Oncology Associates at Mercy Medical Center, Cedar Rapids
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25マイル先
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
被験者募集中第2相
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25マイル先
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25マイル先
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
被験者募集中第2相
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25マイル先
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
被験者募集中第3相
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25マイル先
A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
被験者募集中第1/2相
- University of Iowa Hospital, Iowa City · 25マイル先
A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
被験者募集中観察研究
- University of Iowa Hospital and Clinics, Iowa City · 25マイル先
High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)
被験者募集中第1相
- University of Iowa Health Care, Iowa City · 25マイル先
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
被験者募集中第1/2相
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City · 25マイル先
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
被験者募集中第3相
- University of Iowa Stead Family Children's Hospital, Iowa City · 25マイル先
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
被験者募集中第3相
- University of Iowa, Iowa City · 25マイル先
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
被験者募集中第1相
- University of Iowa Hospitals & Clinics, Iowa City · 25マイル先
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
被験者募集中第3相
- University of Iowa Hospitals and Clinics, Iowa City · 25マイル先
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
被験者募集中観察研究
- University of Iowa, Iowa City · 25マイル先
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
被験者募集中第1相
- University of Iowa Hospitals & Clinics, Iowa City · 25マイル先
他の都市における急性骨髄性白血病の試験
- Houston, TX85件の研究
- New York City, NY51件の研究
- Boston, MA44件の研究
- Baldwin Park, CA40件の研究
- Seattle, WA40件の研究
- Columbus, OH35件の研究
- Philadelphia, PA34件の研究
- Durham, NC33件の研究
- Atlanta, GA30件の研究
- Tampa, FL29件の研究
- Chicago, IL26件の研究
- Portland, OR25件の研究
Cedar Rapidsにおける他の研究
- 非小細胞肺癌20件の研究
- 乳がん17件の研究
- がん（全種類）15件の研究
- 多発性骨髄腫15件の研究
- 肺がん14件の研究
- 大腸癌13件の研究
- 前立腺がん12件の研究
- 頭頸部扁平上皮癌12件の研究
- 悪性黒色腫10件の研究
- 脳卒中10件の研究
- 転移性癌9件の研究
- 子宮内膜がん9件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。